Novel nanoformulated chemotherapeutics and diagnostics require demonstration of efficacy and safety in appropriate animal models prior to clinical translation of the concept. Pharmacokinetic studies are also important to optimize dosing regimen and dose escalation strategy, and identify potential species differences. NCL’s in vivo experiments are tailored specifically to the individual nanoparticle under study.  As such, a standard experimental protocol cannot be generated.  Instead of a protocol, we offer the following general guidance for experimental design and data analysis. The following description is not a protocol and does not describe all of the relevant experimental parameters necessary to conduct the experiment. If you would like additional information, please feel free to contact us.

• Guide to NCL In Vivo Studies.pdf(PDF | 528 KB)

Researchers should cite this work as follows:

• Stephan Stern (2022). Guide to NCL In Vivo Studies: Efficacy, Pharmacokinetics & Toxicology. NCI Hub. doi:10.17917/W63A-GR02

  BibTex | EndNote

1. Efficacy
2. nanoparticles nanomedicine
3. pharmacokinetics
4. toxicity